Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "PharmaTimes" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about PharmaTimes for you to read. Along with our medical data and news we also list PharmaTimes Clinical Trials, which are updated daily. BioPortfolio also has a large database of PharmaTimes Companies for you to search.
The Lancet has published data from Kyowa Hakko Kirin Co’s successful Phase III trial of immunotherapy Poteligeo underpinning its recent approval in the US to treat in patients with cutaneous T-cell lymphoma (CTCL).
Scientists have discovered a marker in the blood that could predict the risk of developing kidney cancer.
ViiV Healthcare and Janssen have unveiled positive headline data from a late-stage trial of their injectable two-drug regimen for the treatment of HIV.
GP practices across London have successfully made the switch to using the Electronic Prescription Service (EPS), saving hours of time and money, NHS Digital says.
Emergency hospital visits are more common among patients with bowel cancer living in the most deprived areas of the country than for those living in affluent regions, research funded by Cancer Research UK has found.
The Scottish Medicines Consortium has approved funding for four newly licensed medicines, expanding NHS treatments options in Scotland for ovarian cancer, lung cancer, urea cycle disorders and acute hereditary angioedema.
Roche/Novartis’ Xolair has been awarded breakthrough status in the US for treatment of severe allergic reactions after accidental exposure to foods allergens.
The National Institute for Health and Care Excellence is not recommending NHS use of Biogen’s Spinraza for the rare genetic disorder spinal muscular atrophy (SMA) at this time.
US regulators have accepted for review a targeted, Gram-positive investigational antibiotic developed by UK biopharma Motif Bio for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
UK-American biotech Orchard Therapeutics has raised $150 million to fuel development of its gene therapy pipeline.
Bowel cancer screening in England and Wales is to start a decade earlier in a drive to pick up more cases of the disease at an earlier stage, the government has confirmed.
Amicus Therapeutics’ Galafold has been approved in the US as the first oral medication for the treatment of adults with Fabry disease.
Astellas has acquired Cambridge, UK-based Quethera, a gene therapy group focused on the development of novel treatments for ocular disorders, such as glaucoma.
The US Food and Drug Administration has approved Alnylam’s RNAi therapeutic Onpattro for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Janssen ranks first in new survey of pharma's reputation among mental health patient groups
PharmaTimes Media has announced the Medical & Scientific Excellence Awards as the latest addition to its highly prestigious portfolio of events.
The PharmaTimes Communications Team of the Year competition is the only pharma industry awards that tests the competencies and potential of communications agency teams, benchmarking talent agency side. This year sees the introduction of a new 'Charity Challenge', which in partnership with Beating Bowel Cancer and Bowel Cancer UK, will focus on a real life scenario for the first time.
Director of policy and communications at MSD and executive steering group member Harry Brady looks at how the PharmaTimes Marketer and Communications Team of the Year competitions have evolved to embrace the importance of cross-functional working and the value of great healthcare communications in the marketing mix.
Oversubscribed financing includes investment from Pfizer and Novartis
Strong performances for Mavenclad and Bavencio
Chairman says consumer and Rx platforms are "navigating divergent industry dynamics"
San Diego-based Ligand would acquire programmes in respiratory, oncology and CNS
Following an appeal the drug will now be available to treat ALL
Takeda has committed $100 million, including the participation in the Series A financing, to Ambys